Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN: Atrasentan in IgA Nephropathy at Risk of Progressive Renal Function Loss
2020-003084-26Phase 3Active
- Sponsor
- Chinook Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Atrasentan with Placebo (2 arms). Primary endpoint: Change in proteinuria (UPCR) at Week 36. Started Dec 2020; status: active.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-003084-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003084-26.